Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synsam ABCHIX:SYNSAS 82 3-Year EBITDA Growth Rate is 11.90% as of Jun. 2026, which is at its 10-year median of 11.90. GuruFocus rates CHIX:SYNSAS with a GF Score™ of 82/100 and a GF Value™ of kr62.03. The stock has 1 warning sign investors should review. Among 688 Medical Devices & Instruments companies, Synsam AB ranks better than 54.36% on this metric.
During the past 12 months, Synsam AB's average EBITDA Per Share Growth Rate was 18.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 11.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Synsam AB was 31.80% per year. The lowest was 8.60% per year. And the median was 11.90% per year.
Synsam AB (CHIX:SYNSAs) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Synsam AB 3-Year EBITDA Growth Rate Related Terms
CHIX:SYNSAS vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Synsam AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synsam AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Synsam AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Synsam AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.90% mean?
Synsam AB (CHIX:SYNSAS) has a 3-Year EBITDA Growth Rate of 11.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Synsam AB and its competitors. This is near median its historical median of 11.90. Over the past decade, Synsam AB's 3-Year EBITDA Growth Rate has ranged from 8.60 to 31.80. According to the industry distribution chart, Synsam AB ranks #314 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 45.6%.
Is Synsam AB's 3-Year EBITDA Growth Rate too high?
Synsam AB's current 3-Year EBITDA Growth Rate of 11.90% is near median its 10-year median of 11.90. Over the past 10 years, this metric has ranged from a low of 8.60 to a high of 31.80. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.90. Synsam AB's value of 11.90% is 50.6% above this industry median. Based on the distribution chart, Synsam AB ranks #314 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Synsam AB has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Synsam AB's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Synsam AB ranks #314 out of 688 companies for 3-Year EBITDA Growth Rate. This puts Synsam AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.90. Synsam AB's value of 11.90% is 50.6% above this benchmark. Historically, Synsam AB's own 3-Year EBITDA Growth Rate has ranged from 8.60 to 31.80 over the past decade. While the company's 10-year median is 11.90 vs. the industry median of 7.90, Synsam AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synsam AB's current 3-Year EBITDA Growth Rate of 11.90% is 50.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Synsam AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synsam AB's current 3-Year EBITDA Growth Rate is 11.90%, which is near median its own 10-year median of 11.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synsam AB stock overvalued right now?
Synsam AB (CHIX:SYNSAS) has a current 3-Year EBITDA Growth Rate of 11.90%. The stock's GF Value™ is kr62.03, compared to a current price of kr59.80 — trading 3.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 11.90%, which is near median its 10-year median of 11.90 and 50.6% above the Medical Devices & Instruments industry median of 7.90. Synsam AB's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Synsam AB (CHIX:SYNSAS), the current 3-Year EBITDA Growth Rate is 11.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synsam AB (CHIX:SYNSAS) Overvalued in 2026?
Based on GuruFocus' analysis, Synsam AB stock appears to be undervalued.
The current stock price of kr59.80 is trading 3.6% below its estimated GF Value™ of kr62.03.
Key valuation signals for CHIX:SYNSAS:
3-Year EBITDA Growth Rate: 11.90% (near median its 10-year median of 11.90)
GF Value™: kr62.03 vs. price of kr59.80 (3.6% below fair value)
Industry Position: 50.6% above the Medical Devices & Instruments median (#314 of 688)
No single metric tells the full story. See the CHIX:SYNSAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synsam AB is a lifestyle company in optics and eye health in the Nordic region. The company offers various products and services in physical and digital stores, such as eye examinations, spectacles, sunglasses, sports spectacles, contact lenses, and accessories in optical retail, as well as spectacles subscriptions and related services under the name Synsam Lifestyle. Its stores are operated under the Synsam brand in Sweden, Norway, and Finland, and under the Profil Optik brand in Denmark and Iceland. The company comprises four segments: Sweden, which generates key revenue, Denmark, Norway, and Finland.
82GF Score
Get the complete analysis for CHIX:SYNSAS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SYNSAS has been successfully added to your 
